Kivett L, Taintor J, Wright J
Foundation Equine Mobile Medicine and Dentistry, Southern Pines, NC, USA.
J Vet Pharmacol Ther. 2014 Aug;37(4):413-6. doi: 10.1111/jvp.12097. Epub 2013 Dec 20.
Simultaneous administration of a nonselective COX inhibitor and a COX-2 specific NSAID has not been previously reported in horses. The goal of this study was to determine the safety of a 10-day dosage regimen of phenylbutazone and firocoxib, both at their standard dosages, in horses. Six horses were administered 2.2 mg/kg of phenylbutazone and 0.1 mg/kg of firocoxib by mouth, daily for 10 days. Horses were assessed daily for changes in behavior, appetite, fecal consistency, signs of abdominal pain, and oral mucous membrane ulceration. Horses were assessed prior to and on the last day of treatment for changes in serum creatinine, albumin, total protein, and urine-specific gravity. Horses underwent endoscopic examination of the esophagus, stomach, and pylorus prior to and 24 hours after the last treatment. A significant change in serum creatinine and total protein was observed on day 10 of treatment. No other significant findings were noted during the experiment. Results indicated that co-administration of phenylbutazone and firocoxib may cause renal disease.
此前尚未有关于马同时使用非选择性COX抑制剂和COX-2特异性非甾体抗炎药（NSAID）的报道。本研究的目的是确定按标准剂量同时给予苯基丁氮酮和氟罗昔康10天给药方案对马的安全性。6匹马每天口服2.2mg/kg苯基丁氮酮和0.1mg/kg氟罗昔康，持续10天。每天评估马的行为、食欲、粪便稠度、腹痛体征和口腔黏膜溃疡情况。在治疗前和治疗最后一天评估马的血清肌酐、白蛋白、总蛋白和尿比重变化。在最后一次治疗前和治疗后24小时对马进行食管、胃和幽门的内镜检查。在治疗第10天观察到血清肌酐和总蛋白有显著变化。实验期间未发现其他显著结果。结果表明，同时给予苯基丁氮酮和氟罗昔康可能会导致肾脏疾病。
